Search Results
Jun 17, 2025, 10:30 ET King Faisal Specialist Hospital & Research Centre and Germfree Laboratories Announce Landmark Advanced Therapy Manufacturing Campus in Riyadh
said Kevin Kyle, CEO of Germfree Laboratories. "Together, we are building much more than a facility for Cell & Gene Therapy manufacturing, we're building a turnkey, scalable platform for discovery and delivery of curative therapies for the people of Saudi
More news about: Germfree Laboratories LLC
Jun 17, 2025, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rocket Pharmaceuticals, Inc. - RCKT
action] On May 27, 2025, Rocket issued a press release "announc[ing] an update related to RP-A501, its investigational gene therapy for Danon disease." The press release disclosed that "[a] patient participating in the Phase 2 pivotal trial of RP-A501 experienced an unexpected
More news about: Pomerantz LLP
Jun 17, 2025, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rocket Pharmaceuticals, Inc. - RCKT
action] On May 27, 2025, Rocket issued a press release "announc[ing] an update related to RP-A501, its investigational gene therapy for Danon disease." The press release disclosed that "[a] patient participating in the Phase 2 pivotal trial of RP-A501 experienced an unexpected
More news about: Pomerantz LLP
Jun 17, 2025, 10:00 ET Genomenon Powers Groundbreaking Study on Genetic Drivers of Rare Liver Disorders
advancing PFIC2 research: A knockin mouse model carrying the common disease-causing E297G variant in the ABCB11 gene developed by Rectify, andA comprehensive, evidence-based catalog of ABCB11 variants, built using Genomenon's Mastermind® Genomic Intelligence
More news about: Genomenon
Jun 17, 2025, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against PepGen Inc. and Certain Officers - PEPG
dystrophy ("DMD"), a genetic disorder characterized by progressive muscle degeneration and weakness. DMD is caused by the mutation of the dystrophin gene, resulting in, inter alia, a limited production of the dystrophin protein, which in turn leads to DMD's clinical features. According to PepGen,
More news about: Pomerantz LLP
Jun 17, 2025, 09:38 ET Makera's Desktop CNC Revolution: How One Company's Innovation Is Transforming Medical Research
of China's premier national research platforms dedicated to advancing stem cell biology, regenerative medicine, and gene editing. Jointly established by the Chinese Academy of Sciences and local governments, the institute creates a comprehensive innovation ecosystem spanning
More news about: Makera
Jun 17, 2025, 08:02 ET Azitra Reports Promising Safety Data from Phase 1b Trial in Netherton Syndrome
approximately one in ten infants with Netherton syndrome die in their first year of life. Netherton syndrome is caused by mutations in the SPINK5 gene, which codes for the serine protease inhibitor Lympho-epithelial Kazal-type related inhibitor, or LEKTI. The function of LEKTI is to inhibit enzymes
More news about: Azitra, Inc.
Jun 17, 2025, 07:03 ET Lutris Pharma to Present Data from Its Phase 2 Trial of LUT014 Gel for the Treatment of Patients With EGFRI-Induced Acneiform Rash at the ESMO Gastrointestinal Cancers Congress 2025
pathway is one of the key pathways that regulate growth, survival, proliferation, and differentiation of cells. B-Raf is a protein encoded by the BRAF gene and is a downstream effector component of the EGFR signaling pathway. EGFR has been shown to be over-activated in various human cancers, including colorectal,
More news about: Lutris Pharma
Jun 17, 2025, 07:03 ET Lutris Pharma to Present Data from Its Phase 2 Trial of LUT014 Gel for the Treatment of Patients With EGFRI-Induced Acneiform Rash at the ESMO Gastrointestinal Cancers Congress 2025
pathway is one of the key pathways that regulate growth, survival, proliferation, and differentiation of cells. B-Raf is a protein encoded by the BRAF gene and is a downstream effector component of the EGFR signaling pathway. EGFR has been shown to be over-activated in various human cancers, including colorectal,
More news about: Lutris Pharma
Jun 17, 2025, 06:53 ET European Direct-to-Consumer Genetic Testing Market to Reach USD 3.78 Billion by 2035, Says Meticulous Research®
fastest CAGR during the forecast period, driven by increasing focus on personalized nutrition, wellness optimization trends, and growing understanding of gene-diet interactions. Next-Generation Sequencing (NGS) Experiencing Highest Growth by Technology The DNA Microarrays segment is expected
More news about: Meticulous Market Research Pvt. Ltd.
Jun 17, 2025, 06:45 ET Lilly to acquire Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk
developing a pipeline of gene editing medicines designed to address the drivers of atherosclerotic cardiovascular disease (ASCVD) through treatments that may only need to be given once in a lifetime. Verve's lead program (VERVE-102) is a potential first-in-class in vivo gene editing medicine targeting
More news about: Eli Lilly and Company
Jun 17, 2025, 03:00 ET RIFT en Kingspan Unidek tekenen allereerste commerciële overeenkomst voor Iron Fuel Technology
maken. "In onze zoektocht naar oplossingen schoten veel technologieën tekort. Wat RIFT biedt is een enorme vooruitgang," zegt Gene Murtagh, CEO van Kingspan. "Wij kunnen de technologie in onze activiteiten integreren zonder dat er een complete
More news about: RIFT | Renewable Iron Fuel Technology
Jun 17, 2025, 03:00 ET RIFT et Kingspan Unidek signent le tout premier accord commercial pour la technologie Iron Fuel
notre recherche de solutions, de nombreuses technologies ont échoué. Ce qu'offre RIFT est rafraîchissant et tangible », déclare Gene Murtagh, CEO de Kingspan. « Il s'intègre à nos opérations sans nécessiter une refonte complète, ce qui permet de traduire les ambitions climatiques
More news about: RIFT | Renewable Iron Fuel Technology